AZD0156: Selective ATM Kinase Inhibitor for Cancer Research

Executive Summary:
AZD0156 is a potent, selective, and orally bioavailable small-molecule inhibitor of ATM kinase, a key regulator of the DNA damage response (DDR) pathway (APExBIO). It exhibits sub-nanomolar inhibitory potency and over 1000-fold selectivity for ATM versus other PIKK family kinases. Preclinical studies show that AZD0156 significantly enhances cancer cell sensitivity to DNA double-strand break-inducing agents (Kostaras et al., 2020). The compound is supported by robust quality control standards from APExBIO, ensuring high-purity and reproducible results. AZD0156 is a critical tool for dissecting checkpoint control, genomic stability, and advancing therapeutic development in oncology research.

Biological Rationale

ATM kinase is a serine/threonine kinase within the phosphatidylinositol 3-kinase-related kinase (PIKK) family. It is activated by DNA double-strand breaks (DSBs) and orchestrates a signaling cascade that promotes DNA repair, cell cycle checkpoints, and cell fate decisions (Kostaras et al., 2020). Dysregulation of ATM function is implicated in tumorigenesis due to compromised genomic stability and altered DNA repair. Inhibitors of ATM, such as AZD0156, allow researchers to probe the consequences of DDR modulation and to evaluate synthetic lethality strategies in oncology (AZD0156: Potent ATM Kinase Inhibitor for Cancer Research ...). This article extends the discussion by providing an updated, verifiable framework for AZD0156's application and specificity.

Mechanism of Action of AZD0156

AZD0156 binds selectively to the ATP-binding site of ATM kinase, inhibiting its catalytic activity. The compound has a molecular weight of 461.56 g/mol and the formula C₂₆H₃₁N₅O₃. Biochemical assays reveal sub-nanomolar IC₅₀ for ATM inhibition in cellular systems, with >1000-fold selectivity over other PIKK members, such as ATR, DNA-PKcs, and mTOR (APExBIO). Inhibition of ATM by AZD0156 disrupts DNA DSB repair, impairs G1/S and G2/M checkpoint activation, and enhances cell death in response to genotoxic therapies. This mechanism enables researchers to dissect DDR pathway dependencies and to explore combination therapy paradigms for cancer treatment (AZD0156: Advanced Perspectives on ATM Kinase Inhibition a...). Here we clarify AZD0156's molecular specificity and experimental advantages over earlier inhibitors.

Evidence & Benchmarks

• AZD0156 inhibits ATM kinase with sub-nanomolar potency (IC₅₀ <1 nM, in vitro kinase assays) (APExBIO).
• Demonstrates >1000-fold selectivity for ATM over ATR, DNA-PKcs, and mTOR in biochemical selectivity panels (APExBIO).
• Enhances sensitivity of human cancer cell lines to DNA double-strand break-inducing agents in preclinical models (Kostaras et al., 2020).
• Oral administration in xenograft models produces significant tumor growth delay when combined with chemotherapeutics that induce DSBs (Kostaras et al., 2020).
• Supplied as a solid, purity >98% by HPLC/NMR; stable at -20°C; soluble at ≥23.1 mg/mL in DMSO with gentle warming, moderately soluble in ethanol (≥5.49 mg/mL), insoluble in water (APExBIO).
• Early-phase clinical studies underway for advanced solid tumors and hematological malignancies (study protocols cited in APExBIO).
• Distinct phosphoproteomic signatures following ATM inhibition reported in translational studies (Kostaras et al., 2020).

Applications, Limits & Misconceptions

AZD0156 is primarily used in research settings to interrogate ATM-dependent DNA repair, checkpoint regulation, and synthetic lethality strategies in oncology. It is also employed to dissect metabolic adaptations following DDR inhibition (AZD0156: A Next-Generation ATM Kinase Inhibitor Revealing...). This article updates earlier reviews by systematically detailing workflow, QC, and clinical translation aspects.

Common Pitfalls or Misconceptions

• AZD0156 is not effective against ATR, DNA-PKcs, or mTOR at relevant concentrations; its specificity must be experimentally confirmed in complex cellular backgrounds.
• The compound is insoluble in water; inappropriate solvents can compromise assay reproducibility and compound stability.
• Long-term storage of solutions is not recommended; stability is optimal at -20°C as a solid and for short-term use in DMSO or ethanol.
• AZD0156 is not a direct cytotoxic agent in the absence of DNA damage; its activity relies on synergy with genotoxic stressors.
• The product is for research use only and is not approved for clinical therapy outside controlled studies.

Workflow Integration & Parameters

For best results, AZD0156 (SKU B7822) should be dissolved at concentrations ≥23.1 mg/mL in DMSO with gentle warming. For moderate solubility, ethanol may be used (≥5.49 mg/mL); avoid water as a solvent. Typical working concentrations in cell-based assays range from 10 nM to 1 μM, depending on cell type and endpoint (AZD0156 (SKU B7822): Scenario-Driven Best Practices for A...). This article clarifies dosing, solvent, and QC considerations beyond previous guides. Solutions should be freshly prepared and used promptly to ensure maximal potency. Shipping is performed on Blue Ice for stability. Quality control data (HPLC, NMR) confirm purity >98% per APExBIO lot release documentation. For protocol optimization and troubleshooting, refer to scenario-driven guidance (see full guide).

Conclusion & Outlook

AZD0156 is a cornerstone reagent for studying the DNA damage response, checkpoint control, and therapeutic sensitization in cancer research. Its sub-nanomolar potency, high selectivity, and robust QC from APExBIO support reproducibility and translational relevance. Ongoing preclinical and clinical studies continue to define its role in combination regimens and biomarker-driven patient selection (Kostaras et al., 2020). For the latest updates and reagent specifications, consult the official AZD0156 product page. For advanced insights on metabolic adaptation and synthetic lethality, see related resources (Precision ATM Inhibition: AZD0156 and the Next Frontier o...), which this article expands by integrating workflow and QC data for laboratory implementation.